HC Wainwright & Co. Maintains Buy on Structure Therapeutics, Lowers Price Target to $100

Benzinga Newsdesk www.benzinga.com Neutral 58.7%

Neg 0% Neu 58.7% Pos 0%

HC Wainwright & Co. analyst Ananda Ghosh maintains Structure Therapeutics (NASDAQ:GPCR) with a Buy and lowers the price target from $114 to $100.